ProQR clinical trial: LCA10

ProQR are conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat LCA 10. Sepofarsen is designed to repair the CEP290 RNA defect and produce a normal functioning CEP290 protein, which will result in improved vision in participants. This study is ongoing in a number of clinical centres in North America and Europe, involving 30 patients over a 25 month period.


More information about the Illuminate trial can be found on the ProQR and Illuminate websites.


To keep up to date with our news and activities,
please leave your details below